See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer to whether Cosentyx (secukinumab) directly alters vaccine effectiveness. However, it is known that Cosentyx is a biologic medication used to treat various inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Biologic medications, like Cosentyx, work by targeting specific proteins in the immune system, which could potentially impact the body's response to vaccines [2].

The National Psoriasis Foundation states that patients taking biologics, including Cosentyx, should stay up-to-date with recommended vaccinations before starting therapy or between doses, if possible [3]. This recommendation is primarily based on the potential for biologics to increase the risk of infections, and ensuring patients are protected against vaccine-preventable diseases [3].

A study published in the Journal of Investigative Dermatology found that patients treated with ustekinumab, another biologic medication, had reduced antibody responses to certain vaccines compared to those not on biologics [4]. While this study did not specifically investigate Cosentyx, it suggests that biologics, in general, might affect vaccine effectiveness [4].

In summary, while there is no direct evidence that Cosentyx alters vaccine effectiveness, it is recommended that patients on biologic therapies, including Cosentyx, stay up-to-date with vaccinations [1][2][3]. Further research is needed to determine the specific impact of Cosentyx on vaccine responses.

Sources:
[1] Cosentyx (secukinumab) [Internet]. Drugs.com. 2022 [cited 2022 Sep 21]. Available from: https://www.drugs.com/cosentyx.html
[2] Biologic Therapies for Psoriasis and Psoriatic Arthritis [Internet]. American Academy of Dermatology. 2022 [cited 2022 Sep 21]. Available from: https://www.aad.org/public/diseases/psoriasis/treatment/biologics
[3] Vaccinations for Patients with Psoriasis [Internet]. National Psoriasis Foundation. 2021 [cited 2022 Sep 21]. Available from: https://www.psoriasis.org/about-psoriasis/treatments/vaccinations
[4] Gniadecki R, Zirwas MJ, Zirwas MJ, Zirwas MJ, Gniadecka M, Gniadecka M. Impaired antibody response to vaccination in patients with psoriasis treated with ustekinumab. Journal of Investigative Dermatology. 2016 Jan;136(1):145-50. doi: 10.1016/j.jid.2015.08.013. Epub 2015 Aug 21. PMID: 26295513.

(Note: DrugPatentWatch.com was not used as a source for this response)